GleamWall
中文EN

PHAT Phathom Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1783183 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY86.8%
TTM net income YoY69.8%
TTM EPS YoY73.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin80.7%
Operating margin-9.3%
Net margin-30.2%
FCF margin-7.7%
EBITDA margin-9.1%

Returns

ROE—
ROA-28.4%
ROIC (approx.)—
Asset turnover0.94x

Leverage & solvency

Liabilities / assets200.8%
Debt / equity—
Current ratio1.76x
Interest coverage-0.41x

Cash quality & payout

Operating cash flow / net income0.25x
Accruals ratio-21.3%
Payout ratio—
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$175.11M$55.25M
Cost of revenue$22.60M$7.97M
Gross profit$152.51M$47.28M
R&D expense$32.78M$34.08M
SG&A expense$279.72M$290.66M
Operating income-$159.99M-$277.47M
Interest expense$68.11M$72.01M
Pretax income-$221.25M-$334.33M
Income tax$0$0
Net income-$221.25M-$334.33M
EBITDA-$159.35M-$276.67M
EPS (basic)-3.03-5.29
EPS (diluted)-3.03-5.29
Weighted avg. shares (diluted)72.92M63.18M
Balance sheet
Cash & equivalents$129.97M$297.26M
Receivables$78.13M$38.80M
Inventory$5.52M$3.21M
Current assets$228.97M$360.13M
PP&E, net$1.06M$1.48M
Total assets$259.15M$378.32M
Current liabilities$132.04M$85.73M
Short-term debt$0$0
Long-term debt$209.09M$201.41M
Total debt$209.09M$201.41M
Total liabilities$697.32M$631.90M
Shareholders' equity-$438.17M-$253.58M
Net debt$79.11M-$95.85M
Shares outstanding71.42M68.52M
Cash flow statement
Operating cash flow-$166.78M-$266.77M
Capital expenditure$229,000$135,000
Free cash flow-$167.00M-$266.90M
Investing cash flow-$229,000-$135,000
Financing cash flow-$288,000$182.77M
Depreciation & amortization$633,000$795,000
Stock-based compensation$28.72M$24.05M

Free plan shows the latest 2 periods; Pro shows all 8 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.